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1 Introduction 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system, 
characterized by demyelination and axon damage (1). Common symptoms of MS include 
paresis and paresthesia, disturbances of gait and coordination, loss of vision and extreme 
fatigue. In most cases, there is complete recovery from the first symptoms, but later the 
disease progress in a relapsing-remitting manner. Typical age of onset is 20-40 years, 
making MS is the most common severe neurological disease of young adults. MS is a 
complex disease with both environmental and genetic risk factors. In Finland, prevalence 
of MS is approximately 1:1000, and twice as high, 2:1000, in the Southern Ostrobothnia 
(2). This difference is thought to be explained at least partly by genetic risk factors 
enriched in the subisolate. To date, no Southern Ostrobothnian specific genetic mutations 
causative for the disease have been identified.  
 
Recent studies in MS genetics emphasize the role of the immune system and enlighten the 
pathology of MS as an autoimmune disease. Variants in genes related to various immune 
cell functions, such as the HLA locus, IL2RA, IL7R, CLEC16A, CD58, TNFRSF1A, 
IRF8, STAT3 and TYK2, have been associated with MS disease (3-7), and these findings 
have just been further verified by a large multicenter collaboration in a genome wide 
association study (GWA) (8). Yet, these variants explain only a fraction of the inheritance 
of the MS disease (8). These studies have been carried out by studying single nucleotide 
polymorphisms (SNPs), which are common in healthy individuals as well. In 2004, Iafrate 
et al published a novel form of genetic variation, further defined by Redon et al and 
McCarroll et al in 2006: variation in copy number of relatively short DNA fragments (copy 
number variations, CNVs) (9-11). CNVs are believed to explain as much of the variance 
between individuals as SNPs (10-11). Since then, the role of CNVs in disease 
susceptibility has been widely studied. 
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Current SNP arrays for genome wide association studies are used to study both SNPs and 
CNVs. We conducted a GWA study for multiple sclerosis using 68 distantly related MS 
cases from Finnish MS high risk sub-isolate of Southern Ostrobotnia and the 
HumanHap300 chip from Illumina. Although the used chip has not been designed for 
monitoring CNVs, we wanted to take a first look of CNVs in MS. We assessed the 
frequency of the identified CNVs by comparison to public databases, and evaluated their 
possible role in the etiology of MS with pathway analyses. Furthermore, we applied an in-
house developed CNV genotyping method to carry out genotyping of three deletions in 
high-through put manner in a nationwide sample set of more than 700 cases and 1000 
controls. 
 
Results of this study have been previously reported in Jakkula, et al, 2010 (7). 
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2 Material and methods 
2.1 Samples 
MS cases, which had either both parents born in the MS high risk region in the Southern 
Ostrobothnia or one isolate-born parent and family history of MS, were selected for the 
study. The diagnosis of MS was determined using Poser’s criteria (12). Peripheral blood 
samples were collected during 1998-2002 and DNA was extracted using conventional 
methods at National Institute of Health and Welfare. The birthplaces of cases and their 
parents were collected and confirmed from national registries. After reviewing the birth 
places and names of the parents, population records were used to gather genealogical data 
up to 5-18 generations back. Two large pedigrees were identified, which date back to 15
th
 
century (Figure 1). 68 MS patients were ascertained to origin from the isolate and were 
selected for genome wide SNP genotyping. 
 
 
Figure 1. MS pedigrees from the high risk region of Southern Ostrobothnia. Although 
profound interrelatedness does exist between the family members, only the shortest 
connections are presented. All family members are not depicted for illustration purposes. 
Figure modified from Jakkula, et al, 2010. 
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2.2 Ethical aspects 
Sample collection and the study design have been approved by the Helsinki University 
Hospital Ethical Committee of Ophthalmology, Otorhinolaryngology, Neurology and 
Neurosurgery (permit 192/E9/02). Informed, written consent was obtained from all patients 
participating to the study. Statistical analyses were performed as a large combined dataset 
and interpreted only as such. No individual genotypes or other personal results were 
reported back to the patients or their family. 
 
2.3 SNP genotyping 
Illumina HumanHap300 SNP genotyping chip consist of arrayed 50 base pair long DNA 
probes complimentary to the known reference sequence next to the 317,503 SNPs to be 
genotyped. Sample DNA is hybridized on the array, followed by single nucleotide 
extension with labeled A, C, G and T nucleotides and imaging of the chip. Illumination of 
the different nucleotides (specified A and B allele signal intensities for either of the alleles 
for each SNP) are measured, and genotypes are assigned with automated algorithms. The 
68 MS cases chosen for the study were genotyped at the Broad Institute, Cambridge, USA, 
with Illumina HumanHap300 chip according to manufacturer’s protocol (Illumina, Inc., 
San Diego, California, USA). SNP ID’s and positions were mapped to NCBI human 
genome build 35 (hg17). 
 
2.4 CNV estimation 
Identification of copy number variations from SNP chip data is based on the signal 
intensity of the SNP genotyping probes (“Log R Ratio”) and the allelic signal intensity (“B 
Allele Freq”) of the SNPs on the length of the chromosomes. For the loci where a 
chromosomal region is duplicated, signal intensities of the SNP probes are multiplied when 
compared to that of the chromosomal regions with normal, haploid copy number, in 
proportion to the number of times the region is duplicated. At the same time, the allelic 
signal intensities of the heterozygote SNPs in the duplicated regions shows typical 
clustering: for triplicated regions, genotype clusters for AAB and ABB genotypes can be 
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identified, for quadrupled regions, genotype clusters for AAAB, AABB and ABBB can be 
identified, and so on. Figure 2(a) shows an example of a triplicated locus. On the other 
hand, for the loci where a chromosomal region is lost and thus the locus is present only in 
one chromosome, the signal intensities of the SNP probes are lower from that of the signal 
intensities of the SNPs in the loci with normal copy number. At the same time 
heterozygous SNPs are lost from the region (Figure 2(b)). If both copies of the locus are 
lost from the chromosomes, resulting in a copy number of 0, signal intensities of the SNP 
probes fall to immeasurable and the allelic signal intensities show typical scattering across 
all possible values. 
 
For this study, CNVs were estimated for the 68 cases using QuantiSNP v1.0 software (13). 
The local G and C base content of the sequence next to the genotyped SNPs affects the 
probe hybridization and the intensities subsequently, so the GC correction option of 
QuantiSNP was used. As recommended by the software authors, only CNVs with a log 
Bayesian factor >10, indicating reliable CNV calls, were included in further analyses. All 
CNV calls were assured visually from the Illumina BeadStudio software’s allelic intensity 
ratio (“B Allele Freq”) and normalized total intensity (“Log R ratio”) scatter plots (Figure 
2). All CNVs with discrepancies between the automatic calls and visual estimation were 
excluded from further analyses. Additionally, centromeric regions were excluded, and only 
the CNVs with three or more SNPs were taken into account. PennCNV software 
(2007Nov13 version (14)) was also used, but as this seemed to yield more false positives 
when the results were visually estimated, its results were not used in further analyses. Copy 
number variations were regarded as same events between the samples if they overlapped in 
chromosomal position. Copy numbers 3 and 4 were regarded jointly as “gain” events and 
copy numbers 0 and 1 as “loss” events. 
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Figure 2. Examples of visual estimation of QuantiSNP CNV calls. Screen captures from 
Illumina BeadStudio showing a typical duplication (a) in the genomic region highlighted 
with green in chromosome 12 with elevated SNP probe signal intensity (Log R Ratio, 
upper panel) and clustered allelic signal intensities (B Allele Freq, lower panel) of 
heterozygous SNPs, and a typical deletion (b) in the genomic region highlighted with 
orange in chromosome 22 with a drop in SNP probe signal intensity and no heterozygous 
SNPs. Blue dots represent individual SNPs. 
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2.5 Pathway analyses 
Pathway analyses were generated through the use of Ingenuity Pathway Analysis 
(Ingenuity
®
 Systems, www.ingenuity.com). Genes mapping near or into the identified 
CNVs were given as an input feed. Pathway growing –option, allowing addition of 5 
molecules, and connect-option, connecting the input and added molecules in the analyses, 
were used. All output pathways were critically studied from literature. 
 
2.6 CNV genotyping 
The copy number variations mapping to a joint pathway (see Results) were further 
genotyped in a larger set of 703 MS cases and 1051 controls from all over Finland. For 
genotyping of the deletions in DLG2, ERBB4 and NRG3 promoter, we used the in-house 
built method (InGoLF, Instant Genotyping of Lost DNA Fragments) described in Sulonen, 
et al, 2009 (15). In SNP based copy number variation estimation the true break points of 
the CNV lie somewhere between the last undeleted or unduplicated SNP and the first 
deleted or duplicated SNP. We sought for the break points by designing primers 
(Primer3Plus (16)) to these “grey zones” sequentially, approximately 1000 base pairs from 
one another, forward-primers to the 5’-end of the estimated deletion and reverse-primers to 
the 3’-end. As we then performed PCR with different primer pair combinations and re-
sequenced the shortest product from the individuals with the estimated deletion, we found 
the exact break points of the deletion. 
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Figure 3. Principle of the InGoLF-genotyping. Schematic presentation of the primer 
design for different alleles for the genotyped deletions. PCR product over the deleted 
region is too long to be efficiently amplified in the genotyping PCR. PCR products from 
the different alleles are of different sizes, and thus the genotypes can be separated by gel 
electrophoresis. Figure modified from Sulonen, et al, 2009. 
 
For the InGoLF-genotyping we designed six different PCR-products across these break 
points, using nine primers: one product from the normal allele and one from the deleted 
allele for each of the three deletions. Schematic presentation of the assay design is given in 
Figure 3. All deletions had one labeled primer (FAM, VIC and NED), used jointly with the 
two different primers for the different alleles. PCR-products from the two alleles for each 
deletion were of different sizes, ranging from 155 base pairs to 565 base pairs. Table 1 
describes the primer design and lengths of the PCR products. PCRs for the deletions in 
DLG2 and NRG3 were done in one multiplex reaction and PCRs for the deletion in ERBB4 
in its own multiplex, each in the following conditions: 10 ng of DNA, 200 nM of the 
labeled forward-primer and 300 nM of the allele specific reverse-primers for the DLG2-
deletion and ERBB4-deletion, 140 nM of labeled forward-primer and 200 nM of allele 
specific reverse-primers for the NRG3-deletion, 0.55 IU of AmpliTaq Gold PCR 
polymerase (Applied Biosystems, Foster City, CA, USA), 1x AmpliTaq reaction buffer 
(Applied Biosystems), 200 µM of dNTP, 1.5 mM on MgCl2 and ddH2O added to the 
reaction volume of 10 µl. The cycling conditions were: initial denaturation in 94 °C for 12 
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minutes; 30 cycles of: denaturation in 94 °C for 30 seconds, primer annealing in 61 °C for 
15 seconds and extension in 72 °C for 45 seconds; final extension in 72 °C for 10 minutes 
and cooling down to 10 °C until further use. The PCR products were pooled together, 
diluted in 2:75 proportions in Hi-Di formamide and run in a single capillary gel 
electrophoresis on an ABI 3730xl DNA Analyzer with LIZ-500 size standard (Applied 
Biosystems). GeneMapper 4.0 software (Applied Biosystems) was used for allele calling 
(Figure 4). 
 
    
PCR product length 
(bp) 
Deletion Forward-primer Label Reverse-primers 
Normal 
allele 
Deleted 
allele 
DLG2 CAACTGCAATTTC
CTTCTGGA 
FAM AGAGTAGAGGCAA
GGCAGCA 
287 0
a
 
   TTTGAAGGGCAGT
TTGCAC 
33,390
b
 217 
ERBB4 GTAAGTCTTGCCC
GAAGCTG 
VIC GGAGGTGGGTGTA
TTTGTTCC 
492 0
a
 
   TGTGAGAACAGGC
CTTGGA 
8613
b
 565 
NRG3 GGGGAAATGATT
GTGGTTCA 
NED AGGGGTGTGGAGG
ATATAGGA 
197 0
a
 
      AAATGCCTGGATC
AAACCAA 
12,119
b
 155 
a
 Reverse-primer annealing locus deleted. 
b
 PCR product too long to be efficiently amplified. 
Table 1. PCR primers used in InGoLF-genotyping 
 
Because InGoLF is currently applicable only for deletions, the duplication in LARGE was 
not genotyped in the larger sample set. The “grey zones” in UTRN deletion were too large 
to be efficiently covered with primers needed in the search for the true break points, and 
thus this deletion was also not genotyped. 
 
  10    
 
Figure 4. Screen shot from the InGoLF genotyping on GeneMapper 4.0. Window 
shows the allele peaks for two different samples from ABI 3730xl capillary gel 
electrophoresis. Both samples are homozygous for the normal allele of NRG3 (black peak, 
197 bp), first sample is heterozygous for the deletion in DLG2 (blue peaks, 217 bp for the 
deleted allele and 287 bp for the normal allele), and both samples are heterozygous for the 
deletion in ERBB4 (green peaks, 492 bp for the normal allele and 565 bp for the deleted 
allele). Orange peaks are LIZ-500 size standard marking different PCR product lengths. 
 
Fisher’s exact test was used to monitor for statistical difference between the frequencies of 
the genotyped deletions in the 703 MS cases and 1051 controls. Fisher’s test was 
considered more suitable than the commonly used χ2-test, as the former allows for data 
point occurrences of less than 5. 
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3 Results 
We found 106 copy number variable regions in the 68 MS cases with QuantiSNP v1.0 
software and visual assurance from the BeadStudio (Appendix 1). Six of the identified 
CNV regions were novel (not listed in the Database of Genomic Variants (August 5
th
, 2009 
updated version, http://projects.tcag.ca/variation/ (9)) (Table 2). All of these were very rare 
events and were found only in one individual. 
 
Chr Start (b35) End (b35) 
Size 
(bp) 
N of 
SNPs 
Copy 
Number type Genes 
2 54354348 54404322 49975 7 loss ACYP2 intron, TSPYL6 
3 24134391 24172277 37887 8 loss THRB, last 6 exons 
9 21743138 21761241 18104 4 gain MTAP promoter 
13 67542909 67552774 9866 3 gain 
 
14 73494691 73538366 43676 4 loss 
COQ6 last 8 exons, 
ENTPD5 exons 1-13 
18 56949141 56950768 1628 3 loss   
Table 2. Novel CNVs detected in MS cases 
 
We reasoned that the genes mapping to all the 106 CNVs identified in the MS cases could 
be members of a common pathway involved in the disease etiology. We tested this 
hypothesis using Ingenuity Pathway Analysis (Ingenuity
®
 Systems, www.ingenuity.com) 
to search for connecting pathways for the genes in the CNV regions. Indeed, we found one 
pathway involving the genes NRG3, ERBB4, DLG2, UTRN and LARGE (Figure 5). This 
pathway potentially regulates oligodendrocyte differentiation and myelin sheet formation. 
Neuregulin 3 (coded by NRG3-gene) is a neural growth factor that inhibits apoptosis of 
oligodendrocyte precursor cells through its receptor ERBB4 and PI3-K-pathway (17). 
DLG2 (PSD-93, chapsyn-110) is likely to be involved in the assembly of ERBB4 to the 
cell membranes, in ERBB4 turnover and neuregulin signaling (18,19). The differentiation 
of oligodendrocyte precursors and the proper formation of myelin sheets by mature 
oligodendrocytes seems to be regulated by interactions between neuregulin-ERBB –
mediated signaling, laminin-2-integrin signaling and laminin-2-dystroglycan (DG) 
signaling (20,21). Though the exact intracellular pathways in laminin-2-dystroglycan 
signaling mediated myelin sheet formation are unknown, dystroglycan is known to bind 
utrophin (UTRN). Utrophin in turn binds β2-syntrophin (SNTB2), which has a binding site 
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for ERBB4 (18), thus potentially enabling direct interactions between ERBB4 and 
dystroglycan-utrophin-complex. Like-glycosyltransferase (LARGE) is an important 
glycosyl transferase for dystroglycan. Mutations in LARGE-gene cause congenital 
muscular dystrophy type 1D (MDC1D), a muscular dystrophy with profound mental 
retardation, white matter changes and subtle structural abnormalities on brain MRI (22). 
 
 
 
Figure 5. Regulation of oligodendrocyte survival and differentiation. NRG3-ERBB4 
enhances oligodendrocyte survival, and together with laminin-2, promotes differentiation. 
When signaling trough dystroglycan (DG) and possibly utrophin (UTRN), laminin-2 
regulates myelin sheet formation. Figure modified from Ingenuity Pathway Analysis 
(Ingenuity
®
 Systems, www.ingenuity.com). (Figure from Jakkula, et al, 2010) 
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Re-sequencing of the break points for deletions in ERBB4, NRG3 and DLG2 revealed the 
true deletions to be in positions chr2:212,892,210-212,900,258, chr10:82,869,397-
82,881,361 and chr11:84,215,352-84,248,525, respectively (UCSC Genome Browser, 
hg18, March 2006 assembly). We used an in-house built method, InGoLF (Instant 
Genotyping of Lost DNA Fragments) to genotype these deletions in 703 MS cases and 
1051 controls from all over Finland. Of the 68 MS cases originally genotyped on Illumina 
HumanHap300 chip, 48 were also genotyped with InGoLF. All the deletions found with 
QuantiSNP were also found with InGoLF. We found one ERBB4 deletion with InGoLF in 
one of these 48 cases that was not detected with QuantiSNP, giving an overall sensitivity 
of 100% and specificity of 99% to the method. 
 
Altogether, we found 69 ERBB4 deletions, 28 NRG3 promoter deletions and 1 DLG2 
deletion in the 703 MS cases. The found DLG2 deletion was the same as the one found 
with QuantiSNP in the original sample set of 68 cases, thus proving this deletion to be a 
rare, single event. The prevalence of the deletions in the control sample was similar; we 
found 124 deletions in ERBB4, 40 deletions in NRG3 promoter and none in DLG2. Results 
of the Fisher’s exact test for the samples genotyped with InGoLF are given in Table 3. We 
found no evidence for association of these deletions to MS disease. The ERBB4 deletion 
seemed to be as common in both the cases and controls originating from the high risk MS 
region in Southern Ostrobothnia as in elsewhere of Finland (frequency of 0.10 in cases and 
0.11 in controls in Southern Ostrobothnia versus 0.11 in cases and 0.11 in controls from 
rest of Finland), whereas the NRG3 promoter deletion was slightly more common in 
Southern Ostrobothnia (0.05 and 0.06 versus 0.04 and 0.03, respectively). 
 
 Deletion Cases (n=703) 
Controls 
(n=1051) 
Fisher's 
Exact test 
  losses 
loss 
frequency losses 
loss 
frequency p-value 
ERBB4 69 0,11 124 0,12 0,388 
NRG3 28 0,04 40 0,04 0,900 
DLG2 1 0,00 0 0,00 0,404 
Table 3. Results of the InGoLF-genotyping of the three pathway deletions 
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4 Discussion 
The two identified extended pedigrees with multiple affected MS patients and common 
ancestry support the hypothesis of a founder effect in the Sothern Ostrobothnia. Such 
founder effect could lead to enrichment of rare, deleterious mutations leading to the 
increased disease risk in the isolate. However, the novel CNVs identified in these distantly 
related MS patients were all seen only in one individual, and are likely not causative for 
the disease. We did not find a single common CNV for all or even the majority of the 
studied MS patients. Given the complex nature of the disease inheritance, this was 
anticipated. 
 
As no single CNV could be identified to be associated with MS in the distantly related 
samples, a combination of CNVs affecting genes on same pathway could result in 
increased disease risk. Our pathway analyses revealed a highly interesting conduit, with 
multiple genes affected by a CNV, involved in oligodendrocyte development and survival. 
Though most of the studies considering the pathway described are performed with cells 
derived from developing murine brain, similar interactions could happen in demyelinated 
white matter during remyelination, and altered protein function could plausibly predispose 
to MS. However, no significant increase in the frequency of these deletions were identified 
when we genotyped the ERBB4, DLG2 and NRG3 deletions in a larger sample set of cases 
and controls. Although no association was detected, there was a slight difference in the 
frequency of NRG3 deletion between the Southern Ostrobothnian samples and samples 
from the rest of Finland. Albeit this may not affect to the increased MS disease risk in the 
subisolate, it emphasizes that similar caution must be taken when studying CNVs as with 
SNP studies in populations with internal substructures (23). 
 
The Illumina HumanHap300 chip is not ideal for copy number variation estimation. Its 
marker density is relatively sparse, and thus only the large CNVs can be detected. The 
mean length of the CNVs we found was over 190 Kb, whereas the mean length of CNVs 
detected on more dense arrays has been less than 27 Kb (24). Moreover, the genomic 
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regions with SNPs that have not passed the conventional quality control steps, such as 
regions with inversions or common duplications and deletions, are underrepresented on the 
Illumina HumanHap300 chip. Thus, SNPs on the array tend to be selected from regions 
without common CNVs. Taking all this to account, we were likely to miss a huge portion 
of common copy number variations. By contrast, we were able to find six new CNVs and 
many rare CNVs. To truly evaluate the effect of rare genetic variations on disease risk 
huge sample sizes and large collaborations are necessary, and thus we could not 
profoundly assess the role of the identified rare CNVs to MS disease in this study. 
However, such large sample collection is impossible from a small subisolate. In an isolated 
population with a founder effect, rare family specific mutations leading to the increased 
disease risk should be considered as well. These cannot be identified with genotyping 
assays designed for common variations. Sequencing of whole genomes of the families 
from Southern Ostrobothnia could enlighten the causes of the increased MS disease risk 
within this region.  
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Appendix 1 
Description of all CNVs found in the MS samples. Table originally published in Jakkula, et al, 2010. 
Chr Start (b35) End (b35) Size (bp) N of SNPs 
Copy 
Number type 
Cases 
(n=68) 
Cases 
freq 
Db of Genomic Variants, 
August 5th 2009 Freeze Genes 
1 2058523 2312823 254301 21 gain 3 4.4% Known variation PRKCZ, C1orf86, SKI, MORN1 
1 12354566 12763485 408920 36 gain 1 1.5% Known variation VPS13D, DHRS3, AADACL4, AADACL3, C1orf158, after TNFRSF1B 
1 102379409 102651711 272303 21 loss 1 1.5% Known variation  
1 120776649 120923841 147193 7 gain 2 2.9% Known variation  
1 193569717 193628745 59029 6 loss 4 5.9% Known variation CFHR4 
2 19443 189678 170236 14 gain 1 1.5% Known variation FAM110C 
2 35725730 35999293 273564 40 loss 1 1.5% Known variation  
2 49511191 49664240 153050 21 loss 2 2.9% Known variation  
2 53071353 53103920 32568 4 loss 1 1.5% Known variation  
2 54354348 54404322 49975 7 loss 1 1.5% NEW ACYP2 intron, TSPYL6 
2 86983132 87615568 632437 3 gain 1 1.5% Known variation CD8B1, PLGLB1, RGPD1 
2 89772948 89932893 159946 3 loss 7 10.3% Known variation  
2 99215459 99306408 90950 4 gain 3 4.4% Known variation TSGA10, C2orf15, LIPT1, MITD1, MRPL30, LYG2, LYG1 
2 110214618 110292098 77481 7 loss 1 1.5% Known variation MALL, NPHP1 
2 212981040 213018166 37127 5 loss 3 4.4% Known variation ERBB4 intron 
2 241106342 241131279 24938 6 gain 1 1.5% Known variation GPC1 
3 41894 108412 66519 8 gain 1 1.5% Known variation CHL1 promoter 
3 4021691 4329697 308007 35 loss 1 1.5% Known variation SETMAR 
3 5383302 5411345 28044 6 loss 1 1.5% Known variation  
3 24134391 24172277 37887 8 loss 1 1.5% NEW THRB, last 6 exons 
3 65166887 65187636 20750 3 loss 1 1.5% Known variation  
3 152993783 153028739 34957 7 loss 3 4.4% Known variation AADAC 
4 84915835 84969552 53718 10 loss 1 1.5% Known variation  
  20    
4 132303980 132685819 381840 24 gain 1 1.5% Known variation  
4 167425804 167482371 56568 8 gain 1 1.5% Known variation After TLL1 
4 190200031 191131631 931601 93 gain 1 1.5% Known variation  
5 19055301 19305295 249995 22 loss 1 1.5% Known variation  
5 97074222 97121798 47577 7 loss 5 7.4% Known variation RIOK2 near 
5 104465860 104510644 44785 3 loss 1 1.5% Known variation  
5 178661436 178854467 193032 25 gain 1 1.5% Known variation ADAMTS2 
6 5496231 5522147 25917 7 loss 1 1.5% Known variation FARS2, intron 
6 29076909 29287216 210308 25 loss 1 1.5% Known variation ZNF311, OR2W1, OR2B3, OR2J3, OR2J2 
6 67044129 67104015 59887 11 loss 5 7.4% Known variation BAI3 promoter 
6 95472452 95649511 177060 9 loss 1 1.5% Known variation  
6 137942200 138003365 61166 21 gain 1 1.5% Known variation OLIG3 promoter, TNFAIP3 promoter 
6 144743809 145071977 328169 32 loss 1 1.5% Known variation UTRN, many exons 
7 3175715 3252673 76959 8 loss 1 1.5% Known variation SDK1, intron 
7 6643875 7123923 480049 54 gain 1 1.5% Known variation C1GALT1 
7 8882102 8996708 114607 23 loss 3 4.4% Known variation After NXPH1 
7 9790639 9877397 86759 9 loss 2 2.9% Known variation  
7 12560343 12685347 125005 17 loss 1 1.5% Known variation  
7 69761016 70029858 268843 22 gain 1 1.5% Known variation After AUTS2, WBSCR17 promoter 
7 70919613 71427575 507963 52 gain 1 1.5% Known variation CALN1, exons 1-3 
7 75690975 76059191 368217 6 gain 1 1.5% Known variation ZP3, DTX2, UPK3B, POMZP3 
7 119899100 119906697 7598 3 loss 1 1.5% Known variation KCND2, intron 
7 152959823 153145033 185211 20 gain 1 1.5% Known variation DPP6 
8 5590045 5591685 1641 3 loss 1 1.5% Known variation  
8 16170358 16306880 136523 11 loss 1 1.5% Known variation MSR1 promoter 
8 87256166 87403084 146919 11 gain 1 1.5% Known variation SLC7A13, WWP1 promoter 
8 92192384 92243291 50908 4 loss 5 7.4% Known variation Hypothetical protein FLJ27355, after OTUD6B, SLC26A7 promoter 
8 137757412 137919630 162219 13 loss 1 1.5% Known variation  
9 5296824 5325470 28647 6 loss 1 1.5% Known variation RLN1 
9 10651370 10676202 24833 7 loss 1 1.5% Known variation PTPRD promoter 
9 21743138 21761241 18104 4 gain 1 1.5% NEW MTAP promoter 
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9 28534375 28556849 22475 5 loss 3 4.4% Known variation LINGO2 
9 69329605 69348516 18912 4 loss 1 1.5% Known variation APBA1, intron 
9 70946694 71169744 223051 32 gain 1 1.5% Known variation TRPM3 promoter & exon1 
9 71310230 71589788 279559 48 gain 1 1.5% Known variation TMEM2 
10 15030375 15100889 70515 6 loss 1 1.5% Known variation DCLRE1C, MEIG1 
10 47013328 47173619 160292 12 gain 12 17.6% Known variation ANXA8 promoter 
10 51457810 51805221 347412 28 gain 1 1.5% Known variation FAM21A, ASAH2, SGMS1 
10 66102105 67710331 1608227 209 loss 1 1.5% Known variation CTNNA3 
10 81567594 82006206 438613 40 gain 1 1.5% Known variation SFTPD, C10orf57, PLAC9, ANXA11 
10 82869699 82875955 6257 3 loss 2 2.9% Known variation NRG3 promoter 
11 38188336 38965147 776812 58 loss 1 1.5% Known variation  
11 84219051 84245672 26622 4 loss 1 1.5% Known variation DLG2, intron 
11 89843914 91455249 1611336 121 loss 1 1.5% Known variation  
11 133873030 134225383 352354 69 gain 1 1.5% Known variation  
12 7884583 8017012 132430 14 gain 5 7.4% Known variation SLC2A14, SLC2A3 
12 31157554 31293957 136404 12 gain 1 1.5% Known variation OVOS2 
12 31898373 31954269 55897 12 gain 2 2.9% Known variation  
12 42212399 42288535 76137 12 loss 2 2.9% Known variation ADAMTS20 
12 81671084 81707620 36537 5 loss 1 1.5% Known variation TMTC2, intron 
12 98788860 98966181 177322 18 gain 1 1.5% Known variation ANKS1B exon1, KIAA0701 last 7 exons 
12 130255197 130339814 84618 11 loss 1 1.5% Known variation  
13 67542909 67552774 9866 3 gain 1 1.5% NEW  
13 83009774 83055928 46155 8 loss 8 11.8% Known variation After SLITRK1  
13 94733590 94779857 46268 11 gain 1 1.5% Known variation ABCC4 promoter & exon1 
13 94797740 94825508 27769 7 gain 1 1.5% Known variation  
14 73494691 73538366 43676 4 loss 1 1.5% NEW COQ6 last 8 exons, ENTPD5 exons 1-13 
15 20347960 20777695 429736 50 gain 1 1.5% Known variation TUBGCP5, CYFIP1, NIPA2, NIPA1 
15 38624662 39476524 851863 53 loss 2 2.9% Known variation CCDC32, RPUSD2, CASC5, RAD51, FAM82C, GCHFR, DNAJC17, 
ZFYVE19, PPP1R14D, SPINT1, RHOV, VPS18, DLL4, CHAC1, INOC1, 
EXDL1, CHP, OIP5, NUSAP1, NDUFAF1 
15 98736980 98770528 33549 5 loss 1 1.5% Known variation LASS3 
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16 21515973 21647775 131803 12 loss 1 1.5% Known variation METTL9, IGSF6, OTOA 
16 81289305 81385638 96334 27 loss 1 1.5% Known variation CDH13, intron 
17 30708148 30792312 84165 14 loss 1 1.5% Known variation SLFN11 promoter & exons 1-4, SLFN12, SLFN13 exon1 
17 38782929 38958044 175116 13 gain 1 1.5% Known variation ARL4D, DHX8, near BRCA1 
17 74878104 74905197 27094 9 gain 1 1.5% Known variation HRNBP3 
18 1917798 1970668 52871 9 loss 1 1.5% Known variation  
18 56949141 56950768 1628 3 loss 1 1.5% NEW  
18 62947038 63159299 212262 31 gain 1 1.5% Known variation After DSEL 
18 64897188 64909977 12790 3 loss 5 7.4% Known variation After hypothetical proteins CCDC102B & TXNDC10. DOK6 promoter 
19 3755701 3786177 30477 9 gain 1 1.5% Known variation KIAA1086, ATCAY promoter, MATK promoter 
19 7658063 7691713 33651 6 gain 1 1.5% Known variation FCER2 whole gene & promoter 
19 48066441 48350666 284226 6 loss 2 2.9% Known variation PSG1, PSG6, PSG7, PSG11, PSG2, PSG5, PSG4, PSG9 
19 59994795 60069820 75026 5 loss 1 1.5% Known variation 
KIR3DP1, KIR2DL4, KIR3DL1, KIR2DS4, KIR3DL2, FCAR & NCR1 
promoter 
20 5219710 5345328 125619 22 loss 1 1.5% Known variation PROKR2 whole gene and promoter 
20 14874333 15089959 215627 38 loss 1 1.5% Known variation MACROD2 
21 18981497 19000295 18799 6 gain 1 1.5% Known variation PRSS7 promoter 
21 43646295 43663581 17287 7 gain 1 1.5% Known variation SNF1LK 
22 20654301 20920813 266513 48 gain 1 1.5% Known variation TOP3B, IGLC1 
22 23974960 24235221 260262 10 gain 2 2.9% Known variation LRP5L 
22 32490635 32503091 12457 6 gain 1 1.5% Known variation LARGE, intron 
X 6317902 7961924 1644023 92 gain 1 1.5% Known variation HDHD1A, STS, VCX, PNPLA4, VCX2 
X 91173351 91262603 89253 5 loss 1 1.5% Known variation PCDH11X intron & exon3 
X 140076396 140280802 204407 30 loss 2 2.9% Known variation SPANXA2 intron 
 
 
  
 
